Why is Lincoln Pharmaceuticals Ltd falling/rising?

Recent Price Movement and Market Context

On 13 March, Lincoln Pharmaceuticals witnessed a notable dip, falling ₹13.95 or 2.26% to close at ₹603.45. This decline forms part of a three-day losing streak during which the stock has shed approximately 4.4% of its value. Intraday, the share price touched a low of ₹596.40, marking a 3.4% drop from recent highs. While the stock remains above its 50-day, 100-day, and 200-day moving averages, it is currently trading below its 5-day and 20-day averages, signalling some short-term weakness.

Despite this recent underperformance, Lincoln Pharmaceuticals has outperformed broader benchmarks over multiple time horizons. Year-to-date, the stock has surged 24.89%, significantly outpacing the Sensex’s decline of 12.50%. Over one year, it has delivered a 14.44% return compared to the Sensex’s modest 1.00% gain. The three-year and five-year returns are even more impressive, with gains of 83.14% and 142.98% respectively, dwarfing the Sensex’s 28.03% and 46.80% over the same periods.

Fundamental Strengths Supporting the Stock

Lincoln Pharmaceuticals benefits from a robust balance sheet, characterised by a low average debt-to-equity ratio of zero, indicating a debt-free status that reduces financial risk. The company’s return on equity (ROE) stands at a respectable 11.2%, suggesting efficient utilisation of shareholder capital. Its price-to-book value ratio of 1.7 reflects a fair valuation, albeit at a premium relative to its peers’ historical averages. This premium valuation is supported by the company’s consistent market-beating performance, having outperformed the BSE500 index over the past three years, one year, and three months.

Investor interest appears to be rising, with delivery volumes on 12 March increasing by 8.11% compared to the five-day average, signalling growing participation despite the recent price decline. The stock’s liquidity remains adequate for moderate trade sizes, facilitating smoother transactions for investors.

Challenges and Reasons Behind the Recent Decline

Despite these positives, several factors have contributed to the recent downward pressure on Lincoln Pharmaceuticals’ share price. The company’s long-term growth trajectory has been modest, with net sales increasing at an annual rate of just 9.03% and operating profit growing at a mere 3.19% over the past five years. This slow growth contrasts with the premium valuation the stock commands, raising concerns about sustainability.

Recent quarterly results have been underwhelming, with the December 2025 half-year reporting the lowest return on capital employed (ROCE) at 15.46%. Operating profit before depreciation, interest, and taxes (PBDIT) for the quarter was ₹23.59 crore, the lowest recorded, and the operating profit margin to net sales dropped to 14.18%, signalling margin pressures. Furthermore, profits have declined by 1.7% over the past year despite the stock’s positive price performance, indicating a disconnect between earnings and market valuation.

Another notable concern is the absence of domestic mutual fund holdings in the company, which stands at 0%. Given that mutual funds typically conduct thorough research and due diligence, their lack of investment may reflect reservations about the company’s valuation or business prospects. This absence could weigh on investor sentiment, especially among institutional participants.

Conclusion: Balancing Long-Term Strengths with Short-Term Weaknesses

Lincoln Pharmaceuticals Ltd’s recent share price decline on 13 March reflects a combination of short-term profit-taking and concerns over its subdued earnings growth and flat recent results. While the stock continues to demonstrate strong long-term returns and maintains a solid financial position with no debt, its premium valuation and lack of institutional backing may be causing caution among investors. The company’s recent operational metrics suggest margin pressures and slower growth, which could be tempering enthusiasm despite rising investor participation.

For investors, the key consideration remains whether Lincoln Pharmaceuticals can translate its market-beating returns into sustained earnings growth and margin improvement. Until then, the stock may experience volatility as the market weighs its fundamental challenges against its historical performance.

Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →